SCHEMBL21001079

SCHEMBL21001079

Nc1cc(N2CCOCC2)cc(F)c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 3/20 0.49
KDM4E B2RXH2 4/20 0.42
LMNA P02545 2/20 0.41
MAOA P21397 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
RPS6KA3 P51812 1/20 0.38
RPS6KA2 Q15349 1/20 0.38
RPS6KA1 Q15418 1/20 0.38
MAPT P10636 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30168922 1.00 LGMN (0.49) LGMNKDM4ELMNAMAOAALDH1A1
SCHEMBL2376896 0.91 LGMN (0.49) LGMNKDM4ELMNAMAOAALDH1A1
SCHEMBL29300844 0.83 LGMN (0.42) LGMNKDM4ELMNAMAOAALDH1A1
SCHEMBL16256305 0.79 KDM4E (0.49) LGMNKDM4ELMNAMAOAALDH1A1
SCHEMBL520439 0.79 LGMN (0.67) LGMNKDM4ELMNAALDH1A1HDAC3
SCHEMBL29710195 0.79 LGMN (0.62) LGMNKDM4ELMNAALDH1A1HDAC3
SCHEMBL18887677 0.79 KDM4E (0.50) LGMNKDM4ELMNAALDH1A1MAPT
SCHEMBL2087889 0.79 LGMN (0.62) LGMNKDM4ELMNAALDH1A1HDAC3
SCHEMBL21001116 0.77 MAPT (0.51) KDM4ELMNAALDH1A1MAPTNPC1
Hydrochloric Acid SCHEMBL28512645 0.76 MAPT (0.50) KDM4ELMNAALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
CN-111655690-B Pyrazolopyridinone compounds 詹森药业有限公司 2023-01-10 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
EP-3713941-B1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-06-22 EP disclosed
EP-3713941-B1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-06-22 EP disclosed
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-05-20 US disclosed
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-05-20 US disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
EP-3740478-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-11-25 EP disclosed
EP-3713941-A1 PYRAZOLOPYRIDINONE COMPOUNDS Janssen Pharmaceutica NV (BE) 2020-09-30 EP disclosed
CN-111655690-A Pyrazolopyridinone compounds 詹森药业有限公司 2020-09-11 CN disclosed
CN-111601799-A Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2020-08-28 CN disclosed
WO-2019101182-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-05-31 WO disclosed
WO-2019101182-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R LGMN 4189/4885KDM4E 1817/4885LMNA 4676/4885
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS FGFR1, FGFR3, FGFR2 LGMN 4590/4885KDM4E 964/4885LMNA 4095/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R LGMN 4189/4885KDM4E 1817/4885LMNA 4676/4885
US-11691970-B2 Pyrazolopyridinone compounds FGFR1, FGFR3, FGFR2 LGMN 4590/4885KDM4E 964/4885LMNA 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.